Preferred Label : Allogeneic CRISPR-Cas9 Engineered Anti-CD19 CAR T-cells CTX112;
NCIt synonyms : Allogeneic Anti-CD19 CAR-T Cells CTX112; Allogeneic CRISPR-Cas9-Engineered Anti-CD19 CAR T Cells CTX112; Allogeneic CRISPR-Cas9 Gene-edited CD19-directed CAR T-cells CTX112; Allogeneic Anti-CD19 CAR CRISPR-edited T Cells CTX112;
NCIt definition : A preparation of human allogeneic T-lymphocytes transduced with a chimeric antigen
receptor (CAR) specific for the tumor-associated antigen (TAA) CD19 and gene-edited
with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease
complex to eliminate endogenous TCR, transforming growth factor-beta receptor II (TGFbRII),
and Regnase-1, with potential immunostimulating and antineoplastic activities. Upon
introduction into the patient, the allogeneic CRISPR-Cas9 engineered anti-CD19 CAR
T-cells CTX112 recognize and bind to CD19-expressing tumor cells. This may result
in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of CD19-positive tumor
cells. Removal of endogenous TCR reduces the risk of graft-versus-host disease (GvHD).
CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage
malignancies. Incorporation of the Regnase-1 and TGFBR2 double knockout increases
the potency, persistence and efficacy of the CAR-T cells and enhances anti-tumor activity.;
Molecule name : CTX 112; CTX-112;
NCI Metathesaurus CUI : CL1906223;
Origin ID : C199293;
concept_is_in_subset
- has_target
